Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
Sign Up to like & getrecommendations! Published in 2019 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/1758835919849753
Abstract: Poly (ADP-ribose) polymerase (PARP) inhibitors were developed with the intention of treating patients with homologous recombination repair deficiency (HRD), specifically for patients with tumours that harbour a BRCA mutation (BRCAm). Evidence from clinical trials to… read more here.
Keywords: parp inhibitors; treatment; sensitive relapsed; ovarian cancer ... See more keywords
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.19.02745
Abstract: PURPOSE A phase II study (ClinicalTrials.gov identifier: NCT00628251) showed activity of olaparib capsules versus pegylated liposomal doxorubicin in patients with germline BRCA-mutated platinum-resistant or partially platinum-sensitive relapsed ovarian cancer. We conducted a phase III trial… read more here.
Keywords: chemotherapy; sensitive relapsed; ovarian cancer; chemotherapy patients ... See more keywords
Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.6002
Abstract: 6002Background: SOLO2 (ENGOT ov-21; NCT01874353) showed that maintenance therapy with the PARP inhibitor olaparib in pts with platinum-sensitive relapsed ovarian cancer (PSROC) and a BRCA mutation ... read more here.
Keywords: pts platinum; relapsed ovarian; sensitive relapsed; ovarian cancer ... See more keywords